Optimising Outcomes in Chronic Myeloid Leukaemia Through Rational Drug Selection Using Predictive Assay Results and Maximising Treatment Free Remissions

尽管慢性髓性白血病的治疗结果一般都很好，但仍存在一些重要问题。在这项资助中，我们建议i)个性化新诊断患者的一线治疗选择，使用可以预测治疗反应的生物标志物；Ii)提高旨在停止治疗的患者的治愈概率，iii)使用超敏感的分子检测疾病以预测疾病复发的风险。

Although outcomes in chronic myeloid leukaemia are generally excellent, a number of important questions remain. In this grant, we propose to i) personalise the selection of frontline treatment for newly diagnosed patients, using biomarkers which can predict treatment response; ii) improve the probability of cure in patients aiming to stop their treatment, and iii) use ultra-sensitive molecular tests for disease detection to predict risk of disease relapse.